EGFR-targeted nanoparticles

**EGFR-targeted nanoparticles** is Prosemble's preclinical precision-oncology nanoparticle programme for EGFR-positive non-small cell lung cancer. The programme uses a protein nanoparticle delivery platform engineered to target epidermal growth factor receptor-positive tumour cells and deliver AI-optimized anticancer drug cocktails, with the intended dual strategy of tumour-selective payload delivery and inhibition of EGFR activity. Exact nanoparticle composition, EGFR-binding ligand, and drug payloads have not been publicly disclosed. ([prosemble.bio](https://prosemble.bio/pipeline/))

Other names

EGFR-targeted NPEGFR-targeted nanoparticles